The state government of São Paulo announced this Thursday (07) that CoronaVac has an efficacy rate of 78% in mild cases of coronavirus infection and 100% in severe cases. The immunizer was developed by the Butantan Institute, in SP, and Chinese biopharmaceutical, Sinovac Biotech. Thus, the definitive registration of the vaccine and the request for emergency use should be requested to Anvisa (National Health Surveillance Agency) in the coming days. The minimum rate recommended by the Agency is 50% and the supplementary data will be announced at a press conference by the state government this afternoon. The Immunization Plan of COVID-19 in SP is expected to start on January 25, totaling 9 million people vaccinated in the first stage, with the application of 18 million doses by the end of March. Priority group 1 consists of health professionals, people aged 60 and over, indigenous and quilombola groups.
This text was translated by machine from Brazilian Portuguese.